Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: johnsto1 who wrote (1790)	10/4/2000 10:21:29 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

I really don't know enough about the trickle down candidates to comment sensibly - you're better off looking on Rick's thread. NBSC is a hybrid that I own (mostly just tagging after Rick) - part low-glamor trickle down stuff and part a high risk, high reward play. I also own a little AKRN and some IVGN, and I guess IGEN is also a possible beneficiary, although clearly not a pure play. Thinking broadly, biotechs can spend money on vanilla lab equipment, fancy lab equipment (MALDI-TOF mass spectrometers and the like), reagents, CRO's, subscriptions to INCY-type databases, combo-chem companies, high-throughput screening companies and equipment, biochips. There is also some lag to be considered, and of course pharma research spending overall still dominates that of the biotechs. Maybe we'll see some tool and service companies that up to now have catered mainly to pharma (like INCY and ABSC) reaching out further to biotech companies. This may sort of be a rising-tide-lifts-all-boats sort of environment, in which case either a broad basket of smaller companies or just going with a few big companies is the sensible way to play. Peter